MicroPort CardioFlow Medtech Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Jeffrey R Lindstrom

Chief Executive Officer (CEO)

CN¥4.0m

Compensación total

Porcentaje del salario del CEO	59.8%
Permanencia del CEO	1.1yrs
Participación del CEO	n/a
Permanencia media de la dirección	3.9yrs
Promedio de permanencia en la Junta Directiva	3.7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jeffrey R Lindstrom en comparación con los beneficios de MicroPort CardioFlow Medtech?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-CN¥349m
Mar 31 2024	n/a	n/a	-CN¥410m
Dec 31 2023	CN¥4m	CN¥2m	-CN¥472m

Compensación vs. Mercado: La compensación total ($USD570.00K) de Jeffrey R está en línea con el promedio de empresas de tamaño similar en el mercado German ($USD809.04K).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Jeffrey R con los resultados de la empresa.

CEO

Jeffrey R Lindstrom (57 yo)

1.1yrs

Permanencia

CN¥4,004,000

Compensación

Mr. Jeffrey R Lindstrom is President, Executive Director & General Manager of MicroPort CardioFlow Medtech Corporation from August 29, 2023. He served as senior director of engineering in Edwards Lifescien...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jeffrey R Lindstrom	President	1.1yrs	CN¥4.00m	sin datos
Liang Zhao	Executive Director & First VP of Total Solutions	2.3yrs	CN¥3.91m	0.058% CN¥ 134.9k
Luying Yan	VP & Executive Director	4yrs	CN¥2.70m	0.042% CN¥ 96.8k
Xiangmei Li	Joint Company Secretary	3.9yrs	sin datos	sin datos
Lok Yee Chan	Joint Company Secretary	3.9yrs	sin datos	sin datos

3.9yrs

Permanencia media

43yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 72X se considera experimentado (3.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jeffrey R Lindstrom	President	1.1yrs	CN¥4.00m	sin datos
Liang Zhao	Executive Director & First VP of Total Solutions	2.3yrs	CN¥3.91m	0.058% CN¥ 134.9k
Luying Yan	VP & Executive Director	4yrs	CN¥2.70m	0.042% CN¥ 96.8k
Jonathan H. Chou	Independent Non-Executive Director	3.7yrs	CN¥254.00k	sin datos
Xia Wu	Non-Executive Director	5.1yrs	sin datos	sin datos
Guoming Chen	Non-Executive Chairman of the Board	4yrs	CN¥3.16m	0.031% CN¥ 71.1k
Junjie Zhang	Non-Executive Director	5.1yrs	sin datos	sin datos
Zhixiang Sun	Independent Non-Executive Director	3.7yrs	CN¥254.00k	sin datos
Jiandong Ding	Independent Non-Executive Director	3.1yrs	CN¥254.00k	0.0012% CN¥ 2.9k

3.7yrs

Permanencia media

47yo

Promedio de edad

Junta con experiencia: La junta directiva de 72X se considera experimentada (3.6 años de antigüedad promedio).

MicroPort CardioFlow Medtech Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 26, 2024

MicroPort Cardioflow Medtech Corporation Announces Executive Changes

Less than half of directors are independent

Less than half of directors are independent

MicroPort CardioFlow Medtech Announces Appointment of Zhao Liang as Executive Director

MicroPort CardioFlow Medtech Corporation Announces Resignation of Wu Guojia as an Executive Director

Recent updates

Now 28% undervalued

First half 2024 earnings released: CN¥0.024 loss per share (vs CN¥0.076 loss in 1H 2023)

Now 56% undervalued after recent price drop

MicroPort CardioFlow Medtech Corporation to Report First Half, 2024 Results on Aug 28, 2024

Now 48% undervalued after recent price drop

Full year 2023 earnings released: CN¥0.20 loss per share (vs CN¥0.19 loss in FY 2022)

Forecast to breakeven in 2026

MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 26, 2024

Full year 2023 earnings released: CN¥0.20 loss per share (vs CN¥0.19 loss in FY 2022)

MicroPort CardioFlow Medtech Corporation to Report Fiscal Year 2023 Results on Mar 27, 2024

Microport Cardioflow Medtech Corporation Receives NMPA Approval for Registration Application of Anchorman LAAC System

MicroPort CardioFlow Medtech Corporation Completes Clinical Implantation Cases in Europe

MicroPort CardioFlow Medtech Corporation Announces First Two Clinical Applications of Third-Generation TAVI Product

First half 2023 earnings released: CN¥0.076 loss per share (vs CN¥0.052 loss in 1H 2022)

MicroPort Cardioflow Medtech Corporation Announces Executive Changes

MicroPort CardioFlow Medtech Corporation to Report First Half, 2023 Results on Aug 29, 2023

New major risk - Share price stability

New minor risk - Share price stability

Less than half of directors are independent

Full year 2022 earnings released: CN¥0.19 loss per share (vs CN¥0.079 loss in FY 2021)

Less than half of directors are independent

Microport Cardioflow Medtech Corporation Announces Registration in Colombia for Alwide Plus Balloon Catheter

First half 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.031 loss in 1H 2021)

MicroPort CardioFlow Medtech Corporation to Report Q2, 2022 Results on Aug 29, 2022

MicroPort CardioFlow Medtech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Microport Cardioflow Medtech Corporation Announces That the Transcatheter Mitral Valve Replacement System Independently Developed by the Group Was Successfully Applied by the Heart Team of Zhongshan Hospital

MicroPort CardioFlow Medtech Announces Appointment of Zhao Liang as Executive Director

Full year 2021 earnings released: CN¥0.079 loss per share (vs CN¥0.23 loss in FY 2020)

MicroPort CardioFlow Medtech Corporation Announces Resignation of Wu Guojia as an Executive Director

Less than half of directors are independent

Full year 2021 earnings released: CN¥0.08 loss per share (vs CN¥0.23 loss in FY 2020)

MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 22, 2022

MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 22, 2022

Microport Cardioflow Medtech Corporation Successfully Registered Vitaflow Liberty Transcatheter Aortic Valve Implantation System in Argentina

Microport Cardioflow Medtech Corporation Announces Ce Mark Registration Application for Vitaflow Libertytm

No longer forecast to breakeven

Forecast to breakeven in 2023

Independent Non-Executive Director Hualiang Jiang has left the company

MicroPort CardioFlow Medtech Corporation to Report Fiscal Year 2020 Results on Mar 30, 2021

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad